KJ 103 - Shanghai Bao Pharmaceuticals
Alternative Names: KJ-103 - Shanghai Bao PharmaceuticalsLatest Information Update: 15 Mar 2022
At a glance
- Originator Shanghai Bao Pharmaceuticals
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 Mar 2022 Preclinical trials in Unspecified in China (Parenteral) (Shanghai Bao Pharmaceuticals pipeline, March 2022).
- 10 Mar 2022 Shanghai Bao Pharmaceuticals plans a phase I trial in Healthy volunteers in New Zealand (IV) (NCT05274659)